All Stories

  1. Cerebrospinal fluid NPTX2 and [18F]FDG PET track serotonergic vulnerability to neurodegeneration in prodromal Alzheimer’s disease
  2. Uncovering Clinical and Functional Neuroimaging Characteristics of Overt Stage Phenotypes Within the α-Synucleinopathy Spectrum
  3. Cerebrospinal Fluid Biomarkers Profiling in Cerebral Amyloid Angiopathy and Relationship With Disease Phenotypes
  4. Clinical Pathways for Diagnosing Neurocognitive Disorders: Insights From Process Mining a Memory Clinic Cohort
  5. Rituximab retreatment guided by CD27+ B-cell count vs. clinical relapse in anti-MAG polyneuropathy: a cost-effective approach with lower cumulative doses
  6. Longitudinal changes in [18F]FDG PET brain metabolism as a prognostic marker in autoimmune encephalitis
  7. [18F]FDG PET metabolic correlates of cerebrospinal fluid TAR DNA-binding protein 43 in prodromal Alzheimer's disease
  8. The compensatory effect of education as revealed by resting-state electroencephalographic alpha rhythms in patients with dementia due to Parkinson’s disease: findings from an exploratory study
  9. Neuropsychological and clinical variables associated with cognitive trajectories in patients with Alzheimer's disease
  10. Clinical and metabolic profiles in behavioural frontotemporal dementia: Impact of age at onset
  11. The Many Faces of REM Sleep Behavior Disorder. Providing Evidence for a New Lexicon
  12. Abnormal electroencephalographic rhythms from quiet wakefulness to light sleep in Alzheimer’s disease patients with mild cognitive impairment
  13. Resting-state electroencephalographic rhythms depend on sex in patients with dementia due to Parkinson's and Lewy Body diseases: An exploratory study
  14. Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies
  15. Resting-State EEG Alpha Rhythms Are Related to CSF Tau Biomarkers in Prodromal Alzheimer’s Disease
  16. CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study
  17. Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer’s Disease: A Review and Meta-Analysis
  18. Clinical and biological underpinnings of longitudinal atrophy pattern progression in Alzheimer's disease
  19. Investigating interleukin-8 in Alzheimer's disease: A comprehensive review
  20. Relationship between Posterior Resting-State Electroencephalographic Alpha Rhythms and Cerebrospinal Fluid Biomarkers of Neuropathology in Patients with Alzheimer’s Disease Mild Cognitive Impairment
  21. Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study
  22. Anti-LGI1 encephalitis and Langerhans cell histiocytosis: Two associated entities? A case report
  23. Toward Quantitative Neurology: Sensors to Assess Motor Deficits in Dementia
  24. FDG-PET and ASL MRI identify largely overlapping hypermetabolic and hyperperfusion changes in limbic autoimmune encephalitis
  25. Metabolic and dopaminergic correlates of intellectual enrichment in de-novo Parkinson's disease patients
  26. Limbic Network Derangement Mediates Unawareness of Apathy in Mild Cognitive Impairment due to Alzheimer’s Disease: Clues from [18F]FDG PET Voxel-Wise Analysis
  27. Clinical versus biomarker-based diagnosis of neurocognitive disorders – Authors' reply
  28. Clinical and diagnostic implications of Alzheimer’s disease copathology in Lewy body disease
  29. Resting state electroencephalographic alpha rhythms are sensitive to Alzheimer’s disease mild cognitive impairment progression at a 6-month follow-up
  30. Ma2 antibody‐associated limbic encephalitis: The early etiology treatment may modify the disease clinical trajectory
  31. Autoimmune encephalitis: what the radiologist needs to know
  32. Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer’s disease (AD) mimickers
  33. Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy
  34. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
  35. Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review
  36. Tracking the progression of Alzheimer's disease: Insights from metabolic patterns of SOMI stages
  37. Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword
  38. Alzheimer’s disease (AD) co-pathology in dementia with Lewy bodies (DLB): implications in the disease modification era
  39. COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome
  40. Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease
  41. Sex differences in brain atrophy in dementia with Lewy bodies
  42. Relationship between default mode network and resting-state electroencephalographic alpha rhythms in cognitively unimpaired seniors and patients with dementia due to Alzheimer’s disease
  43. Editorial: CSF and blood biomarkers in COVID-19 and other neuroinfectious diseases
  44. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease
  45. Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort
  46. Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnestic Mild Cognitive Impairment
  47. Right posterior hypometabolism in Pisa syndrome of Parkinson’s disease: A key to explain body schema perception deficit?
  48. Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson’s Disease (PD) and dementia with Lewy bodies (DLB)
  49. Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements
  50. Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy
  51. European consensus for the diagnosis of MCI and mild dementia: Preparatory phase
  52. Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder
  53. A case of Huntington disease‐like 2 in a patient of African ancestry: the everlasting support of clinical examination in the molecular era
  54. The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson’s Disease
  55. Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments
  56. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease
  57. Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy
  58. Case Report: Post-COVID-19 Vaccine Recurrence of Guillain–Barré Syndrome Following an Antecedent Parainfectious COVID-19–Related GBS
  59. Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
  60. Neurological long-COVID in the outpatient clinic: Two subtypes, two courses
  61. The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort
  62. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data
  63. The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer’s Disease and Frontotemporal Dementia
  64. Case 4: Parkinson’s Disease with Onset as Mild Cognitive Impairment (MCI)
  65. Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer’s disease
  66. Polysomnographic correlates of sleep disturbances in de novo, drug naïve Parkinson’s Disease
  67. Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy
  68. Abnormal sweating and “skin flushing” as possible predictive factor for treatment related fluctuations in Guillain-Barré syndrome: a case series and a review of the literature
  69. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
  70. A case series of parainfectious Guillain-Barré syndrome linked to influenza A (H1N1) virus infection
  71. Dopaminergic and Serotonergic Degeneration and Cortical [ 18 F ]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease
  72. Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection
  73. FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration
  74. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients
  75. Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer’s Disease (MCI-AD)
  76. Sex differences in neuroimaging biomarkers in healthy subjects and dementia
  77. Rapid eye movement sleep behavior disorder: A proof‐of‐concept neuroprotection study for prodromal synucleinopathies
  78. Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools
  79. Neuroimaging Findings in Mild Cognitive Impairment
  80. Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease
  81. The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease
  82. Utility of quantitative EEG in early Lewy body disease
  83. Bendamustine–rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy
  84. Brain Aging, Cardiovascular Diseases, Mixed Dementia, and Frailty in the Oldest Old: From Brain Phenotype to Clinical Expression
  85. Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study
  86. Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study
  87. The fate of patients with REM sleep behavior disorder and mild cognitive impairment
  88. Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia
  89. Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years
  90. Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer’s Disease and Inconclusive First Biomarker
  91. Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study
  92. Serum neurofilament light chain rate of change in Alzheimer’s disease: potentials applications and notes of caution
  93. Could arterial spin labelling perfusion imaging uncover the invisible in N ‐methyl‐ d ‐aspartate receptor encephalitis?
  94. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI
  95. Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer’s Disease
  96. 18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease
  97. Increased incidence of axonal Guillain‐Barré syndrome in La Spezia area of Italy: A 13‐year follow‐up study
  98. N-methyl-d-aspartate receptor antibody-related pathologies and pre-existent mental state disorders
  99. Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease
  100. Getting the high school diploma with only one hemisphere: a case report
  101. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD)
  102. Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier
  103. Machine Learning Based Analysis of FDG-PET Image Data for the Diagnosis of Neurodegenerative Diseases
  104. Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers
  105. Clinical utility and research frontiers of neuroimaging in movement disorders